Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials - PubMed
3 hours ago
- #Type 2 inflammation
- #COPD
- #Dupilumab
- Dupilumab reduced exacerbations and symptom severity in COPD patients with type 2 inflammation.
- The drug improved lung function and quality of life over 52 weeks.
- Dupilumab was found to be safe and well-tolerated in two phase 3 trials.